172 related articles for article (PubMed ID: 10848786)
21. Thalidomide in newly diagnosed multiple myeloma and overview of experience in smoldering/indolent disease.
Rajkumar SV
Semin Hematol; 2003 Oct; 40(4 Suppl 4):17-22. PubMed ID: 15015892
[TBL] [Abstract][Full Text] [Related]
22. Unstable plasma thalidomide concentration in patients with refractory multiple myeloma.
Kodama T; Horiuchi R; Tsukamoto N; Nojima Y; Murakami H
Lab Hematol; 2004; 10(3):132-6. PubMed ID: 15479647
[TBL] [Abstract][Full Text] [Related]
23. Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trial.
Popat R; Brown SR; Flanagan L; Hall A; Gregory W; Kishore B; Streetly M; Oakervee H; Yong K; Cook G; Low E; Cavenagh J;
Lancet Haematol; 2016 Dec; 3(12):e572-e580. PubMed ID: 27843120
[TBL] [Abstract][Full Text] [Related]
24. Phase 2 study of pegylated liposomal doxorubicin, vincristine, decreased-frequency dexamethasone, and thalidomide in newly diagnosed and relapsed-refractory multiple myeloma.
Hussein MA; Baz R; Srkalovic G; Agrawal N; Suppiah R; Hsi E; Andresen S; Karam MA; Reed J; Faiman B; Kelly M; Walker E
Mayo Clin Proc; 2006 Jul; 81(7):889-95. PubMed ID: 16835968
[TBL] [Abstract][Full Text] [Related]
25. Thalidomide in patients with advanced multiple myeloma.
Yakoub-Agha I; Moreau P; Leyvraz S; Berthou C; Payen C; Dumontet C; Grosbois B; Beris P; Duguet C; Attal M; Harousseau JL; Facon T;
Hematol J; 2000; 1(3):186-9. PubMed ID: 11920188
[TBL] [Abstract][Full Text] [Related]
26. Use of simple hematological, biochemical and clinical parameters to monitor response of multiple myeloma patients on high dose thalidomide therapy.
Uppal G; Raina V; Sharma A; Anand M; Kumar R; Khaitan BK; Grover JK
Indian J Cancer; 2005; 42(1):46-50. PubMed ID: 15805692
[TBL] [Abstract][Full Text] [Related]
27. Long-term results of thalidomide in refractory and relapsed multiple myeloma with emphasis on response duration.
Cibeira MT; Rosiñol L; Ramiro L; Esteve J; Torrebadell M; Bladé J
Eur J Haematol; 2006 Dec; 77(6):486-92. PubMed ID: 16978238
[TBL] [Abstract][Full Text] [Related]
28. Thalidomide treatment of resistant or relapsed multiple myeloma patients.
Hus M; Dmoszynska A; Soroka-Wojtaszko M; Jawniak D; Legiec W; Ciepnuch H; Hellmann A; Wolska-Smolen T; Skotnicki A; Manko J;
Haematologica; 2001 Apr; 86(4):404-8. PubMed ID: 11325647
[TBL] [Abstract][Full Text] [Related]
29. Thalidomide in multiple myeloma: past, present and future.
Harousseau JL
Future Oncol; 2006 Oct; 2(5):577-89. PubMed ID: 17026450
[TBL] [Abstract][Full Text] [Related]
30. Hyperfractionated cyclophosphamide in combination with pulsed dexamethasone and thalidomide (HyperCDT) in primary refractory or relapsed multiple myeloma.
Kropff MH; Lang N; Bisping G; Dominé N; Innig G; Hentrich M; Mitterer M; Südhoff T; Fenk R; Straka C; Heinecke A; Koch OM; Ostermann H; Berdel WE; Kienast J
Br J Haematol; 2003 Aug; 122(4):607-16. PubMed ID: 12899716
[TBL] [Abstract][Full Text] [Related]
31. Discordant response or progression in patients with myeloma treated with thalidomide-based regimens.
Anagnostopoulos A; Hamilos G; Zorzou MP; Grigoraki V; Anagnostou D; Dimopoulos MA
Leuk Lymphoma; 2004 Jan; 45(1):113-6. PubMed ID: 15061206
[TBL] [Abstract][Full Text] [Related]
32. Intermediate dose thalidomide (200 mg daily) has comparable efficacy and less toxicity than higher doses in relapsed multiple myeloma.
Wechalekar AD; Chen CI; Sutton D; Reece D; Voralia M; Stewart AK
Leuk Lymphoma; 2003 Jul; 44(7):1147-9. PubMed ID: 12916866
[TBL] [Abstract][Full Text] [Related]
33. Use of melphalan, thalidomide, and dexamethasone in treatment of refractory and relapsed multiple myeloma.
Srkalovic G; Elson P; Trebisky B; Karam MA; Hussein MA
Med Oncol; 2002; 19(4):219-26. PubMed ID: 12512915
[TBL] [Abstract][Full Text] [Related]
34. Successful treatment of multiple myeloma relapsing after high-dose therapy and autologous transplantation with thalidomide as a single agent.
Zomas A; Anagnostopoulos N; Dimopoulos MA
Bone Marrow Transplant; 2000 Jun; 25(12):1319-20. PubMed ID: 10871741
[TBL] [Abstract][Full Text] [Related]
35. Combination therapy with thalidomide, incadronate, and dexamethasone for relapsed or refractory multiple myeloma.
Ochiai N; Yamada N; Uchida R; Fuchida S; Okano A; Hatsuse M; Okamoto M; Ashihara E; Shimazaki C
Int J Hematol; 2005 Oct; 82(3):243-7. PubMed ID: 16207598
[TBL] [Abstract][Full Text] [Related]
36. Thalidomide before and after autologous stem cell transplantation in recently diagnosed multiple myeloma (HOVON-50): long-term results from the phase 3, randomised controlled trial.
van de Donk NW; van der Holt B; Minnema MC; Vellenga E; Croockewit S; Kersten MJ; von dem Borne PA; Ypma P; Schaafsma R; de Weerdt O; Klein SK; Delforge M; Levin MD; Bos GM; Jie KG; Sinnige H; Coenen JL; de Waal EG; Zweegman S; Sonneveld P; Lokhorst HM
Lancet Haematol; 2018 Oct; 5(10):e479-e492. PubMed ID: 30290905
[TBL] [Abstract][Full Text] [Related]
37. The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis.
Terpos E; Kastritis E; Roussou M; Heath D; Christoulas D; Anagnostopoulos N; Eleftherakis-Papaiakovou E; Tsionos K; Croucher P; Dimopoulos MA
Leukemia; 2008 Dec; 22(12):2247-56. PubMed ID: 18769451
[TBL] [Abstract][Full Text] [Related]
38. [Bortezomib-based combination therapy for relapsed or refractory multiple myeloma].
Yuan ZG; Hou J; Wang DX; Fu WJ; Chen YB; Xi H
Zhonghua Nei Ke Za Zhi; 2008 Feb; 47(2):102-6. PubMed ID: 18683793
[TBL] [Abstract][Full Text] [Related]
39. Thalidomide as salvage therapy for VAD-refractory multiple myeloma prior to autologous PBSCT.
Ahmad I; Islam T; Chanan-Khan A; Hahn T; Wentling D; Becker JL; McCarthy PL; Alam AR
Bone Marrow Transplant; 2002 Apr; 29(7):577-80. PubMed ID: 11979306
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
